Sun, Dec 28, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Lyxor Global Hedge Fund Index up + 1.4% in October, lifting YTD gains to 4.3%

Monday, November 15, 2010
Opalesque Industry Update - The Lyxor Global Hedge Fund Index, an investable index based on Lyxor’s hedge funds platform which tracks the overall hedge fund universe, was up + 1.4% in October, lifting year to date gains to 4.3%.

Financial markets continued a number of September’s strong trends into October, although the price trajectories were not quite as extreme. US equities posted solid gains, and some of the USD-related plays experienced very solid returns. For example, commodity indexes gained in the high single digits, the euro gained value, gold gained approximately 2%, and silver gained double digits. Long-dated Treasury yields rose sharply, but short and medium-dated paper was roughly flat on the month. Credit spreads declined; the net result was continued positive gains in the High Yield space. Anticipation of QE2, it almost goes without saying, was the dominant market concern. A less important event appeared to be the U.S. midterm election. Corporate earnings provided no major surprises.

October’s trends generally worked for futures-oriented managers. The Lyxor Global Macro Index gained 3% on the month, and the Lyxor CTA Long-Term Index gained 3.2% (taking the year-to-date return to 10.1%). Still-popular long positions in long-dated bond futures were a performance drag for many managers, but long positions in most other asset classes dominated the performances. The CTA Short-Term Index also posted a positive, albeit much more modest return of 0.7%.

Event-Driven managers typically lagged their macro-oriented peers. The Lyxor Merger Arbitrage Index gained 0.3%. The strategy was particularly impacted by spread widening for a well-known deal in the chemical sector; arbs had been pricing the deal very aggressively in anticipation of further bids. The Special Situations Index gained 1.8% in spite of declines in many financial firm shares. The Lyxor Distressed Index lose 0.5%.

The Lyxor Fixed Income Arbitrage Index lose 0.1% and the L/S Credit Index gained 2.2%, pushing its year-to-date performance to 10.6%. Managers in both strategies were able to benefit from gains in emerging markets debt and currency. The Lyxor Convertible & Volatility Arbitrage Index was up 1.7% in October 2010. The strong demand for yield has exacerbated the impact of modest issuance in the convertibles market; the result has been a noticeable tightening in convert pricing.

Directional equity managers had excellent raw material with which to work, and the L/S Equity Long Bias Index gained 1.7% on the month. The L/S Equity Variable Bias gained 1%.

Less directional equity managers continue to wallow in their struggles. The L/S Equity Market Neutral Index posted a -0.5% decline. The L/S Equity Statistical Arbitrage Index gained 0.6% but is still down -1.4% on the year as managers continue to struggle with the “risk on/risk off” environment.

(press release)

Download full press release and performance table here: www.lyxor.com/news-press.php


BG

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hong Kong-Shanghai stock link fails to live up to expectation so far[more]

    Komfie Manalo, Opalesque Asia: In a report, Reuters said that demand has been subdued with the bulk of activities coming from short-term speculative investors. Las

  2. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  3. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  4. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for

  5. CFTC Revokes Registrations of Illinois Resident Aleks A. Kins and Chicago-based AlphaMetrix, LLC[more]

    Matthias Knab, Opalesque: The U.S. Commodity Futures Trading Commission (CFTC) today announced that it has revoked the registration of Aleks A. Kins of Chicago, Illinois, as an Associated Person and the registrations of AlphaMetrix, LLC (AlphaMetrix), a Delaware limited liability company with its